EFTR - eFFECTOR Therapeutics, Inc.
Previous close
0.1891
-11.761 -6,219.408%
Share volume: 0
Last Updated: Tue 02 Jul 2024 08:03:49 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$11.95
-11.76
-98.42%
Fundamental analysis
25%
Profitability
18%
Dept financing
25%
Liquidity
34%
Performance
30%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
-3.85%
6 Months
-87.90%
1 Year
-99.68%
2 Year
-91.07%
Key data
Company detail
CEO: Stephen T. Worland
Region: US
Website: effector.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: effector.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
eFFECTOR Therapeutics, Inc. engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E)
Recent news